5-bromo-N-(4-fluorophenyl)pyridin-2-amine | 918305-48-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-bromo-N-(4-fluorophenyl)pyridin-2-amine
• 英文别名: (5-bromopyridin-2-yl)-(4-fluorophenyl)amine
• CAS: 918305-48-3
• 化学式: C₁₁H₈BrFN₂
• 分子量: 267.1
• InChiKey: MDIJJMBTVYKGEZ-UHFFFAOYSA-N

物化性质

• 沸点：
  326.8±37.0 °C(Predicted)
• 密度：
  1.579±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为产物：
  描述：

  5-溴-2-氯吡啶 、 4-氟苯胺 在 1,1'-bis[bis(dimethylamino)phosphino]ferrocene 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 为溶剂， 反应 15.0h， 以83%的产率得到5-bromo-N-(4-fluorophenyl)pyridin-2-amine
  参考文献：
  名称：

  与多卤代吡啶在Pd催化的胺化中反转常规化学选择性

  摘要：

  报道了一种能够在Pd催化的3,2-和5,2- Br / Cl-吡啶的胺化反应中实现选择性氯化物官能化的新型催化剂体系。利用配体参数化的反应优化策略导致鉴定出1,1'-双[双（二（二甲基氨基）膦基]二茂铁“ DMAPF”，一种易于获得但尚未使用的二膦，作为该转化的独特有效配体。

  DOI：

  10.1021/jacs.7b05409

文献信息

• Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1741708A1

  公开（公告）日：2007-01-10

  The present invention relates to N-alkylamides of the formula I, in which A, Het, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的N-烷基酰胺， 其中A、Het、X、R1、R2和R3具有权利要求中所指示的含义，这些化合物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，公式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备公式I化合物的方法，包括它们的药物组合物，以及利用公式I化合物制造用于刺激内皮型一氧化氮合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals
  申请人：STROBEL Harmut

  公开号：US20080167342A1

  公开（公告）日：2008-07-10

  The present invention relates to N-alkylamides of the formula I, in which A, Het, X, R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及以下公式I的N-烷基酰胺，其中A、Het、X、R1、R2和R3具有声明中指出的含义，这些化合物调节内皮型一氧化氮(NO)合酶的转录，并是有价值的药理活性化合物。具体而言，公式I的化合物上调内皮型NO合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或规范降低的NO水平的情况。本发明还涉及制备公式I化合物的方法，包括它们的制药组合物，以及使用公式I化合物制造用于刺激内皮型NO合酶表达或用于治疗各种疾病，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏衰竭等的药物的用途。
• HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS
  申请人：Sanofi-Aventis

  公开号：EP1904476B1

  公开（公告）日：2009-02-25
• US8642620B2
  申请人：——

  公开号：US8642620B2

  公开（公告）日：2014-02-04
• [EN] HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS<br/>[FR] AMIDES A SUBSTITUTION HETEROARYLE COMPRENANT UN GROUPE DE LIAISON INSATURE OU CYCLIQUE ET LEUR UTILISATION EN TANT QU'AGENTS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS DEUTSCHLAND

  公开号：WO2007000248A1

  公开（公告）日：2007-01-04

  [EN] The present invention relates to N-alkylamides of the formula (I), in which A, Het, X, R¹, R² and R³ have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
  [FR] La présente invention concerne des N-alkylamides de formule (I), où A, Het, X, R¹, R² et R³ ont les significations indiquées dans les revendications. Ces composés modulent la transcription de l'oxyde citrique (NO) synthase endothéliale et sont des composés pharmacologiquement actifs d'une grande utilité. En particulier, les composés de formule régulent de manière positive l'expression de l'enzyme NO synthase endothéliale et peuvent être appliqués dans des conditions visant une expression accrue de ladite enzyme, un taux accru de NO ou la normalisation d'un taux réduit de NO. Cette invention concerne également des procédés de préparation de composés de formule I, des compositions pharmaceutiques comprenant ces derniers et l'utilisation de composés de formule I pour la fabrication d'un médicament destiné à stimuler l'expression de la NO synthase endothéliale ou à traiter diverses maladies, y compris les affections cardiovasculaires telles que l'athérosclérose, la thrombose, les maladies coronariennes, l'hypertension et l'insuffisance cardiaque, par exemple.